Back to top
more

HealthEquity (HQY)

(Delayed Data from NSDQ)

$91.84 USD

91.84
642,993

+0.89 (0.98%)

Updated Aug 7, 2025 04:00 PM ET

After-Market: $91.82 -0.02 (-0.02%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth A Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 40% (98 out of 246)

Industry: Medical Services

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Homology Medicines (FIXX) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research

Homology Medicines (FIXX) delivered earnings and revenue surprises of -25.53% and 23.62%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

PINC or HQY: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

PINC vs. HQY: Which Stock Is the Better Value Option?

Zacks Equity Research

Is G1 Therapeutics (GTHX) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how G1 Therapeutics (GTHX) and HealthEquity (HQY) have performed compared to their sector so far this year.

Zacks Equity Research

PINC vs. HQY: Which Stock Is the Better Value Option?

by Zacks Equity Research

PINC vs. HQY: Which Stock Is the Better Value Option?

Zacks Equity Research

HealthEquity (HQY) Moves 5.3% Higher: Will This Strength Last?

by Zacks Equity Research

HealthEquity (HQY) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

Zacks Equity Research

Is G1 Therapeutics (GTHX) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Here is how G1 Therapeutics (GTHX) and HealthEquity (HQY) have performed compared to their sector so far this year.

Zacks Equity Research

Zacks Industry Outlook Highlights HealthEquity, AMN Healthcare and ModivCare

by Zacks Equity Research

HealthEquity, AMN Healthcare and ModivCare have been highlighted in this Industry Outlook article.

Urmimala Biswas headshot

3 Medical Services Stocks Braving Near-Term Industry Headwinds

by Urmimala Biswas

The Zacks Medical - Services industry is growing on digital healthcare adoption. HQY, AMN and MODV are set to gain the most. However, staffing shortages may disrupt the trend.

Zacks Equity Research

HealthEquity (HQY) Q2 Earnings Lag Estimates, Margins Down

by Zacks Equity Research

HealthEquity (HQY) witnesses solid growth in HSAs, besides recording robust performances in majority of its segments, in the second quarter of fiscal 2023.

Zacks Equity Research

HealthEquity (HQY) Misses Q2 Earnings Estimates

by Zacks Equity Research

HealthEquity (HQY) delivered earnings and revenue surprises of -2.94% and 1.35%, respectively, for the quarter ended July 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

HealthEquity (HQY) Upgraded to Buy: What Does It Mean for the Stock?

by Zacks Equity Research

HealthEquity (HQY) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks Equity Research

Premier, Inc. (PINC) Beats Q4 Earnings and Revenue Estimates

by Zacks Equity Research

Premier, Inc. (PINC) delivered earnings and revenue surprises of 1.67% and 1.61%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

XpresSpa Group, Inc. (XSPA) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

XpresSpa Group, Inc. (XSPA) delivered earnings and revenue surprises of 20% and 1.24%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Onconova Therapeutics, Inc. (ONTX) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

Onconova Therapeutics, Inc. (ONTX) delivered earnings and revenue surprises of 5% and 5%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

ICLR vs. HQY: Which Stock Should Value Investors Buy Now?

by Zacks Equity Research

ICLR vs. HQY: Which Stock Is the Better Value Option?

Zacks Equity Research

Has Elevance Health, Inc. (ELV) Outpaced Other Medical Stocks This Year?

by Zacks Equity Research

Here is how Elevance Health (ELV) and HealthEquity (HQY) have performed compared to their sector so far this year.

Zacks Equity Research

What's in Store for West Pharmaceutical (WST) in Q2 Earnings?

by Zacks Equity Research

West Pharmaceutical's (WST) second-quarter results are likely to reflect strength in the Proprietary Products business.

Zacks Equity Research

Ecolab (ECL) to Report Q2 Earnings: What's in the Offing?

by Zacks Equity Research

Ecolab's (ECL) second-quarter results are likely to reflect continued strength in its Global Industrial segment.

Zacks Equity Research

Stryker (SYK) to Report Q2 Earnings: What's in the Cards?

by Zacks Equity Research

Stryker's (SYK) second-quarter results are likely to reflect strong segmental performances. However, the resurgence of COVID-19 infections is likely to have hurt sales growth.

Zacks Equity Research

Has HealthEquity (HQY) Outpaced Other Medical Stocks This Year?

by Zacks Equity Research

Here is how HealthEquity (HQY) and Intra-Cellular Therapies (ITCI) have performed compared to their sector so far this year.

Zacks Equity Research

Why Is HealthEquity (HQY) Down 10% Since Last Earnings Report?

by Zacks Equity Research

HealthEquity (HQY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

Here's Why HealthEquity (HQY) is Poised for a Turnaround After Losing 7.7% in 4 Weeks

by Zacks Equity Research

HealthEquity (HQY) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Zacks Equity Research

Here's Why You Should Hold on to Accuray (ARAY) Stock For Now

by Zacks Equity Research

Investors continue to be optimistic about Accuray (ARAY) owing to its solid global reach.

Zacks Equity Research

Catalent (CTLT) Inks Deal With MigVax for Oral COVID-19 Vaccine

by Zacks Equity Research

Catalent's (CTLT) latest agreement is expected to significantly boost global COVID-19 vaccination drives.

Zacks Equity Research

BD's (BDX) New Tie-Up to Develop Detection Kit for Monkeypox

by Zacks Equity Research

BD's (BDX) partnership with CerTest is expected to aid in advancing the understanding of the monkeypox virus' global spread.